Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
RedHill Biopharma (NASDAQ: RDHL ) has replaced its existing 2015 co-commercialization agreement with Daiichi Sankyo ( OTCPK:DSKYF ) for Movantik (naloxegol) with a new royalty-bearing agreement, under April 2020 acquisition agreement with AstraZeneca (NYSE: AZN ) . More news on: Red...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2021 Q1 earnings Read more ...
Daiichi Sankyo ( OTCPK:DSKYF ) : Q1 GAAP EPS of ¥49.07. Revenue of ¥236.95B (-5% Y/Y) Press Release More news on: Daiichi Sankyo Company, Limited, Daiichi Sankyo Company, Limited, Earnings news and commentary, Financial stocks news,
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Spot gold traded as high as $1,943.93 per ounce overnight, eclipsing the previous record of $1920.30 set in September 2011 (it has...
AstraZeneca (NYSE: AZN ) has entered into a global development and commercialization agreement with Daiichi Sankyo ( OTCPK:DSKYF ) for latter's DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), for non-small cell lung cancer and triple negative breast cancer. More new...
Source: ClearBridge Investments Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Thermo Fisher Scientific (NYSE: TMO ) will co-develop a companion diagnostic assay for antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan-nxki) with Daiichi Sankyo ( OTCPK:DSKYF ) that will leverage TMO's Oncomine Dx Target Test. More news on: Thermo Fisher Scientific Inc., Daii...
AstraZeneca (NYSE: AZN ) and collaboration partner Daiichi Sankyo ( OTCPK:DSKYF ) announce positive data from a Phase 2 clinical trial, DESTINY-Gastric01, evaluating Enhertu (fam-trastuzumab deruxtecan-nxki) in patients with HER2-positive unresectable/metastatic gastric or gastroesophageal...
Daiichi Sankyo Co Ltd (DSKYF) Q4 2019 Earnings Conference Call April 27, 2020, 03:00 ET Company Participants Sunao Manabe - President & Group CEO Wataru Takasaki - Executive Officer & Head, R&D Division Toshiaki Sai - CFO, EVP & Head, Corporate Strategy Confere...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2020 Q1 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...